Do analysts prefer CERS or UTMD?

Cerus currently has a consensus target price of $4.00, suggesting a potential upside of 48.70%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts clearly believe Cerus is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CERS or UTMD?

In the previous week, Cerus had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 5 mentions for Cerus and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.54 beat Cerus' score of 0.71 indicating that Utah Medical Products is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Utah Medical Products 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend UTMD or SMTI?

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 1.80%. Given Sanara MedTech's higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Do analysts prefer UTMD or EMBC?

Embecta has a consensus target price of $11.00, suggesting a potential upside of 120.44%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Does the media refer more to UTMD or EMBC?

In the previous week, Utah Medical Products had 1 more articles in the media than Embecta. MarketBeat recorded 2 mentions for Utah Medical Products and 1 mentions for Embecta. Utah Medical Products' average media sentiment score of 1.54 beat Embecta's score of 0.00 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Embecta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RXST or UTMD?

RxSight currently has a consensus target price of $8.37, suggesting a potential upside of 33.65%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to RXST or UTMD?

In the previous week, RxSight had 1 more articles in the media than Utah Medical Products. MarketBeat recorded 3 mentions for RxSight and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.54 beat RxSight's score of 1.20 indicating that Utah Medical Products is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Utah Medical Products 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate UTMD or OSUR?

OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 21.47%. Given OraSure Technologies' higher probable upside, analysts clearly believe OraSure Technologies is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 OraSure Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer UTMD or OSUR?

In the previous week, Utah Medical Products had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Utah Medical Products and 1 mentions for OraSure Technologies. Utah Medical Products' average media sentiment score of 1.54 beat OraSure Technologies' score of 0.00 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OraSure Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Utah Medical Products (UTMD) Competitors

$71.62 +0.07 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$71.68 +0.05 (+0.08%)

As of 04:10 PM Eastern

Compare

UTMD vs. CERS, SMTI, EMBC, RXST, and OSUR

Should you buy Utah Medical Products stock or one of its competitors? Utah Medical Products's main competitors and comparable companies include Cerus (CERS), Sanara MedTech (SMTI), Embecta (EMBC), RxSight (RXST), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Utah Medical Products compare to Cerus?

Cerus (NASDAQ:CERS) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Cerus has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Utah Medical Products has a net margin of 29.04% compared to Cerus' net margin of -3.06%. Utah Medical Products' return on equity of 8.74% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Utah Medical Products	29.04%	8.74%	8.50%

78.4% of Cerus shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cerus currently has a consensus target price of $4.00, suggesting a potential upside of 48.70%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts clearly believe Cerus is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cerus had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 5 mentions for Cerus and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.54 beat Cerus' score of 0.71 indicating that Utah Medical Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Utah Medical Products	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Utah Medical Products has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.63	-$15.63M	-$0.03	N/A
Utah Medical Products	$36.11M	6.32	$11.29M	$3.28	21.84

Summary

Utah Medical Products beats Cerus on 9 of the 16 factors compared between the two stocks.

How does Utah Medical Products compare to Sanara MedTech?

Utah Medical Products (NASDAQ:UTMD) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Utah Medical Products has a net margin of 29.04% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Utah Medical Products' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
Sanara MedTech	-29.15%	29.72%	2.84%

Utah Medical Products has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$36.11M	6.32	$11.29M	$3.28	21.84
Sanara MedTech	$109.81M	2.88	-$37.56M	-$3.59	N/A

In the previous week, Utah Medical Products had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for Utah Medical Products and 0 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.88 beat Utah Medical Products' score of 1.54 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Utah Medical Products	Very Positive
Sanara MedTech	Very Positive

Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 1.80%. Given Sanara MedTech's higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Utah Medical Products beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.

How does Utah Medical Products compare to Embecta?

Utah Medical Products (NASDAQ:UTMD) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Utah Medical Products pays an annual dividend of $1.24 per share and has a dividend yield of 1.7%. Embecta pays an annual dividend of $0.04 per share and has a dividend yield of 0.8%. Utah Medical Products pays out 37.8% of its earnings in the form of a dividend. Embecta pays out 2.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Utah Medical Products has increased its dividend for 3 consecutive years. Utah Medical Products is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Utah Medical Products had 1 more articles in the media than Embecta. MarketBeat recorded 2 mentions for Utah Medical Products and 1 mentions for Embecta. Utah Medical Products' average media sentiment score of 1.54 beat Embecta's score of 0.00 indicating that Utah Medical Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utah Medical Products	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Utah Medical Products. Embecta is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$36.11M	6.32	$11.29M	$3.28	21.84
Embecta	$1.08B	0.26	$95.40M	$1.48	3.37

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Embecta has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Embecta has a consensus target price of $11.00, suggesting a potential upside of 120.44%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Utah Medical Products has a net margin of 29.04% compared to Embecta's net margin of 8.59%. Utah Medical Products' return on equity of 8.74% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
Embecta	8.59%	-19.25%	10.82%

Summary

Utah Medical Products beats Embecta on 11 of the 18 factors compared between the two stocks.

How does Utah Medical Products compare to RxSight?

RxSight (NASDAQ:RXST) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

78.8% of RxSight shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 8.0% of Utah Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

RxSight currently has a consensus target price of $8.37, suggesting a potential upside of 33.65%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Utah Medical Products has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.94	-$38.94M	-$1.13	N/A
Utah Medical Products	$36.11M	6.32	$11.29M	$3.28	21.84

RxSight has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Utah Medical Products has a net margin of 29.04% compared to RxSight's net margin of -36.80%. Utah Medical Products' return on equity of 8.74% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Utah Medical Products	29.04%	8.74%	8.50%

In the previous week, RxSight had 1 more articles in the media than Utah Medical Products. MarketBeat recorded 3 mentions for RxSight and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.54 beat RxSight's score of 1.20 indicating that Utah Medical Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Utah Medical Products	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Utah Medical Products beats RxSight on 9 of the 16 factors compared between the two stocks.

How does Utah Medical Products compare to OraSure Technologies?

Utah Medical Products (NASDAQ:UTMD) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Utah Medical Products has a net margin of 29.04% compared to OraSure Technologies' net margin of -43.70%. Utah Medical Products' return on equity of 8.74% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
OraSure Technologies	-43.70%	-19.09%	-16.26%

In the previous week, Utah Medical Products had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Utah Medical Products and 1 mentions for OraSure Technologies. Utah Medical Products' average media sentiment score of 1.54 beat OraSure Technologies' score of 0.00 indicating that Utah Medical Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utah Medical Products	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
OraSure Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Utah Medical Products has higher earnings, but lower revenue than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$36.11M	6.32	$11.29M	$3.28	21.84
OraSure Technologies	$112.41M	2.34	-$68.73M	-$0.69	N/A

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by insiders. Comparatively, 4.7% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 21.47%. Given OraSure Technologies' higher probable upside, analysts clearly believe OraSure Technologies is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Utah Medical Products beats OraSure Technologies on 11 of the 15 factors compared between the two stocks.

Get Utah Medical Products News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTMD vs. The Competition

Export

Metric	Utah Medical Products	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$228.04M	$5.84B	$7.29B	$12.71B
Dividend Yield	1.74%	1.75%	2.54%	10.79%
P/E Ratio	21.84	26.16	271.39	24.10
Price / Sales	6.32	69.41	604.58	77.05
Price / Cash	16.04	33.71	29.03	36.90
Price / Book	1.92	6.18	11.18	6.40
Net Income	$11.29M	$149.30M	$3.46B	$348.28M
7 Day Performance	2.01%	0.89%	1.98%	0.92%
1 Month Performance	6.67%	8.83%	7.32%	5.10%
1 Year Performance	17.53%	7.23%	24.76%	16.16%

Utah Medical Products Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTMD Utah Medical Products	2.2366 of 5 stars	$71.62 +0.1%	N/A	+17.4%	$228.04M	$36.11M	21.84	180	Positive News
CERS Cerus	2.05 of 5 stars	$2.76 -7.1%	$4.00 +44.9%	+122.1%	$600.54M	$206.13M	N/A	290
SMTI Sanara MedTech	1.7627 of 5 stars	$34.17 +0.5%	$35.00 +2.4%	+1.5%	$313.77M	$103.12M	N/A	60
EMBC Embecta	2.8882 of 5 stars	$5.10 -0.6%	$11.00 +115.7%	-63.6%	$290.67M	$1.02B	3.45	1,850
RXST RxSight	2.5068 of 5 stars	$6.37 -1.7%	$8.37 +31.3%	-32.7%	$286.58M	$134.48M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTMD) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Utah Medical Products (UTMD) Competitors

UTMD vs. CERS, SMTI, EMBC, RXST, and OSUR

How does Utah Medical Products compare to Cerus?

Summary

How does Utah Medical Products compare to Sanara MedTech?

Summary

How does Utah Medical Products compare to Embecta?

Summary

How does Utah Medical Products compare to RxSight?

Summary

How does Utah Medical Products compare to OraSure Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTMD vs. The Competition

Utah Medical Products Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Utah Medical Products (UTMD) Competitors

UTMD vs. CERS, SMTI, EMBC, RXST, and OSUR

How does Utah Medical Products compare to Cerus?

Which has more risk & volatility, CERS or UTMD?

Is CERS or UTMD more profitable?

Do institutionals & insiders hold more shares of CERS or UTMD?

Do analysts prefer CERS or UTMD?

Does the media refer more to CERS or UTMD?

Which has higher earnings and valuation, CERS or UTMD?

Summary

How does Utah Medical Products compare to Sanara MedTech?

Do institutionals and insiders hold more shares of UTMD or SMTI?

Is UTMD or SMTI more profitable?

Which has better valuation and earnings, UTMD or SMTI?

Does the media favor UTMD or SMTI?

Which has more volatility & risk, UTMD or SMTI?

Do analysts recommend UTMD or SMTI?

Summary

How does Utah Medical Products compare to Embecta?

Is UTMD or EMBC a better dividend stock?

Does the media refer more to UTMD or EMBC?

Which has better earnings and valuation, UTMD or EMBC?

Do institutionals & insiders have more ownership in UTMD or EMBC?

Which has more volatility and risk, UTMD or EMBC?

Do analysts prefer UTMD or EMBC?

Is UTMD or EMBC more profitable?

Summary

How does Utah Medical Products compare to RxSight?

Do insiders & institutionals have more ownership in RXST or UTMD?

Do analysts rate RXST or UTMD?

Which has preferable earnings & valuation, RXST or UTMD?

Which has more volatility & risk, RXST or UTMD?

Is RXST or UTMD more profitable?

Does the media refer more to RXST or UTMD?

Summary

How does Utah Medical Products compare to OraSure Technologies?

Is UTMD or OSUR more profitable?

Does the media prefer UTMD or OSUR?

Which has higher earnings & valuation, UTMD or OSUR?

Do institutionals and insiders have more ownership in UTMD or OSUR?

Which has more volatility & risk, UTMD or OSUR?

Do analysts rate UTMD or OSUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTMD vs. The Competition

Utah Medical Products Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools